Representational image
Representational image
Text Size:

New Delhi: The Drug Controller General of India (DGCI) has given “restricted emergency use” approval to Itolizumab, a drug used to cure skin ailment psoriasis, for treating Covid-19 patients with moderate-to-severe acute respiratory distress.

Itolizumab is a ‘humanised monoclonal antibody’ developed by the Bangalore-based biopharmaceutical company, Biocon, in collaboration with the Centre for Molecular Immunology (CIM) in Cuba.

Monoclonal antibodies are antibodies produced by immune cells that are cloned from one parent immune cell. These antibodies are designed to bind to a specific type of proteins.

In the case of Itolizumab, it selectively targets CD6, a protein found in the outer membrane of T-cell. T-cell is a type of white blood cell that plays a central role in the body’s immune response.

Protein CD6 is important for the continued activity of T-Cells when the body encounters a foreign pathogen.

However, in case of the Covid-19 infection, sometimes the immune system goes into an overdrive — a process known as cytokines storm — causing inflammation and organ damage.

Itolizumab, by binding to CD6, down regulates T-cell activation, and causes reduction in synthesis of pro-inflammatory cytokines.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.

SUBSCRIBE NOW

The drug has previously been shown to be effective for treating psoriasis, an autoimmune disease in which skin cells build up and form scales and itchy, dry patches.

Biocon had started developing the molecule in collaboration with the Centre for Molecular Immunology (CIM). The company’s scientific team then started developing the antibody for auto-immune diseases in 2006 in India.

Conduct further clinical trials: Health ministry

Biocon received approval for the drug from the DCGI in January 2013.

In May, the company received permission from DGCI to repurpose the drug for Covid-19 treatment.

The trials of the drug were conducted in New Delhi, Mumbai and Bengaluru.

The health ministry has recommended that Biocon must continue to conduct further clinical trials of the drug and also submit a risk management plan to address the safety issues in the post marketing scenario, ThePrint has learnt.

A written, informed consent needs to be obtained from every patient before the drug is administered to the patient. The informed consent form should have factual details about the drug as well as details about alternative therapies available.

According to the documents accessed by ThePrint, the health ministry recommends that the drug can be supplied only on the prescription of a medical specialist and should only be used in hospital settings.

(With inputs from Abantika Ghosh)

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, is among the distinguished founder-investors of ThePrint. Please click here for details on investors.


Also read: Covaxin — India’s first Covid-19 vaccine by Bharat Biotech gets DCGI nod for human trials


 

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

Share Your Views

LEAVE A REPLY

Please enter your comment!
Please enter your name here